NCT05437094

Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740

A Phase 1, Open-Label, Fixed Sequence Study to Investigate the Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740 in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Cardurion Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a Phase 1, single-site, open-label, fixed sequence crossover study to investigate the effect of coadministration of itraconazole on the pharmacokinetics of CRD-740 in healthy male and female subjects. Subjects will be admitted into the study site on Day -1 and will be confined to the study site until discharge on Day 16. Subjects will receive CRD-740 orally on Days 1 and 10. Itraconazole will be given once daily, orally, on Days 7 through 15.

Conditions

• Clinical Pharmacology
• Pharmacokinetics
• Cardiovascular Diseases
• Heart Failure

Interventions

Type	Name	Description
DRUG	CRD-740	CRD-740
DRUG	Itraconazole	Itraconazole

Timeline

• Start date: 2022-06-27
• Primary completion: 2022-08-03
• Completion: 2022-08-10
• First posted: 2022-06-29
• Last updated: 2025-05-15

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study